NASDAQ:PCYC - Pharmacyclics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Pharmacyclics, Inc. is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company's commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer. The Company markets IMBRUVICA in the United States for four United States. Food and Drug Administration (FDA) approved indications for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17 (del 17p CLL); mantle cell lymphoma (MCL) who have received at least one prior therapy, and all lines of Waldenstrom's macroglobulinemia (WM). It is also pursuing the development of IMBRUVICA for Graft versus host disease (GvHD). In addition, it has a pre-clinical testing program underway to develop inhibitors of BTK for inflammatory and autoimmune diseases.

Receive PCYC News and Ratings via Email

Sign-up to receive the latest news and ratings for PCYC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:PCYC
CUSIP71693310
WebN/A
Phone+1-302-6587581

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins2.02%
Return on Equity1.93%
Return on Assets1.52%

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00

Pharmacyclics (NASDAQ:PCYC) Frequently Asked Questions

What is Pharmacyclics' stock symbol?

Pharmacyclics trades on the NASDAQ under the ticker symbol "PCYC."

How were Pharmacyclics' earnings last quarter?

Pharmacyclics, Inc. (NASDAQ:PCYC) posted its quarterly earnings results on Friday, May, 1st. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.11 by $0.02. The biopharmaceutical company had revenue of $206 million for the quarter, compared to analyst estimates of $226.27 million. Pharmacyclics had a net margin of 2.02% and a return on equity of 1.93%. View Pharmacyclics' Earnings History.

How do I buy shares of Pharmacyclics?

Shares of PCYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Pharmacyclics?

Pharmacyclics' mailing address is 1 N Waukegan Rd, NORTH CHICAGO, IL 60064-1802, United States. The biopharmaceutical company can be reached via phone at +1-302-6587581.


MarketBeat Community Rating for Pharmacyclics (NASDAQ PCYC)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  434 (Vote Outperform)
Underperform Votes:  368 (Vote Underperform)
Total Votes:  802
MarketBeat's community ratings are surveys of what our community members think about Pharmacyclics and other stocks. Vote "Outperform" if you believe PCYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PCYC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel